Jump Financial LLC Takes Position in Integer Holdings Co. (NYSE:ITGR)

Jump Financial LLC purchased a new position in Integer Holdings Co. (NYSE:ITGR - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 2,670 shares of the medical equipment provider's stock, valued at approximately $354,000.

Several other hedge funds also recently made changes to their positions in the company. Mather Group LLC. boosted its position in Integer by 304.3% during the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 143 shares during the period. Lee Danner & Bass Inc. acquired a new position in shares of Integer in the 4th quarter valued at $27,000. R Squared Ltd acquired a new stake in shares of Integer during the fourth quarter valued at approximately $44,000. Sterling Capital Management LLC boosted its position in Integer by 472.9% during the 4th quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 279 shares during the period. Finally, Versant Capital Management Inc grew its holdings in shares of Integer by 98.4% during the 4th quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider's stock valued at $49,000 after acquiring an additional 183 shares in the last quarter. Institutional investors and hedge funds own 99.29% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. StockNews.com lowered Integer from a "hold" rating to a "sell" rating in a report on Friday, April 25th. Truist Financial set a $150.00 target price on shares of Integer and gave the company a "buy" rating in a research note on Friday, April 25th. Oppenheimer lowered Integer from an "outperform" rating to a "market perform" rating in a research note on Friday, February 21st. Raymond James lifted their price target on shares of Integer from $145.00 to $150.00 and gave the stock an "outperform" rating in a research note on Friday, April 25th. Finally, KeyCorp reduced their price objective on shares of Integer from $154.00 to $145.00 and set an "overweight" rating for the company in a report on Monday, April 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $145.56.

Integer Price Performance

NYSE:ITGR traded down $0.17 during trading hours on Thursday, reaching $126.14. 70,956 shares of the company were exchanged, compared to its average volume of 346,935. The business has a 50 day moving average of $118.92 and a 200 day moving average of $130.18. Integer Holdings Co. has a 1-year low of $104.93 and a 1-year high of $146.36. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09. The company has a market capitalization of $4.40 billion, a P/E ratio of 37.61, a P/E/G ratio of 1.72 and a beta of 1.09.

Integer (NYSE:ITGR - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The medical equipment provider reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.27 by $0.04. The company had revenue of $437.39 million for the quarter, compared to the consensus estimate of $428.51 million. Integer had a net margin of 6.92% and a return on equity of 11.65%. The firm's quarterly revenue was up 7.3% compared to the same quarter last year. During the same period last year, the company posted $1.14 EPS. Research analysts forecast that Integer Holdings Co. will post 6.01 EPS for the current year.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.